For several years, semaglutide for weight management was available only as a weekly injection. A daily tablet is now available as well, and many people who would rather avoid injections want to know how it compares. This article explains what the tablet is, what its main clinical trial showed and what is different about taking it.
Two tablets with different purposes
Oral semaglutide has existed as a medication for some time, and this history can cause confusion. Rybelsus is an oral semaglutide tablet approved for type 2 diabetes. It is a separate product with a separate indication, and its dosing does not apply to weight management.
The tablet for weight management is sold as Wegovy, the same brand name as the weekly injection. Novo Nordisk announced the U.S. approval of the tablet on December 22, 2025. According to its prescribing information, the tablet is intended for adults with obesity, or adults with overweight and at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. The label also lists a cardiovascular indication for adults with established cardiovascular disease.
How it works
The tablet contains the same active ingredient as the injection. Semaglutide activates the receptor for GLP-1, a hormone the gut releases after eating. The medication signals fullness to the brain and slows the emptying of the stomach. Most people who take it eat less as a result. The difference between the tablet and the injection lies in how the medication enters the body, not in what it does once it is there.
What the main trial showed
The tablet's weight-management approval rests largely on the OASIS 4 trial, published in the New England Journal of Medicine in 2025. The trial enrolled adults without diabetes who had obesity or who were overweight and had at least one obesity-related condition. Participants took either the tablet or a placebo each day, alongside lifestyle support. At week 64, average body weight had fallen by 13.6 percent in the semaglutide group, compared with 2.2 percent in the placebo group.
For context, the STEP 1 trial of the weekly injection reported an average weight reduction of 14.9 percent at week 68, compared with 2.4 percent for placebo. These are separate trials with different participants and designs, so the two results cannot be compared directly. Your provider can help you weigh them for your own situation.
Side effects
Gastrointestinal side effects are the most common problem with either form. In OASIS 4, gastrointestinal adverse events were reported by 74.0 percent of people taking the tablet and by 42.2 percent of people taking placebo. The label lists nausea, diarrhea, vomiting, constipation and abdominal pain among the most common reactions.
The tablet carries the same boxed warning as the injection. In rodents, semaglutide caused thyroid C-cell tumors, and it is unknown whether it causes these tumors in people. For that reason, anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2 (MEN2), should not take it. The label also warns about pancreatitis, gallbladder disease, low blood sugar in people taking insulin or a sulfonylurea, and kidney injury from dehydration. The tablet is not recommended during pregnancy.
Why the way you take it matters
The stomach absorbs only a small amount of semaglutide from a tablet, and food, drinks and other medicines can reduce that amount further. For this reason, the label includes specific instructions about taking the tablet on an empty stomach, with limited water, and waiting before eating, drinking or taking other oral medicines. Your prescriber and the medication guide explain these instructions in full, and following them closely is what allows the tablet to work as intended.
The tablet can also affect how other oral medicines are absorbed. In a drug interaction study, the semaglutide tablet increased exposure to levothyroxine, a common thyroid medication. Anyone who takes daily oral medicines should review them with a provider before starting.
Who might prefer the tablet
The tablet may suit people who strongly prefer not to inject and who can follow a consistent morning routine. The injection may suit people who would rather not manage a daily fasting window or who take several other morning medicines. Neither form is right for everyone, and the choice is a clinical decision made with your provider.
Where Truthe fits
If you and a licensed provider decide that a GLP-1 medication belongs in your plan, the Truthe Rx LEAN program is a physician-prescribed weight-loss program for adults. It offers semaglutide as a weekly injection or as a daily oral form, as well as tirzepatide. Your provider can explain how the oral form offered through LEAN compares with the branded tablet. Truthe does not prescribe, and an independent licensed provider decides whether a prescription is appropriate for you.
Disclaimer: This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any medication.
Sources
- Wharton S, et al. Oral semaglutide in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PMID 40934115. doi.org/10.1056/NEJMoa2500969
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185. doi.org/10.1056/NEJMoa2032183
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets, prescribing information (NDA 218316, revised 2026): indications, boxed warning, dosage and administration, warnings and precautions, drug interactions. accessdata.fda.gov
- Epocrates. FDA approves oral Wegovy pill for weight loss (report of the December 22, 2025 approval). epocrates.com
Ready to Start?
Explore personalized treatment plans designed around your goals. Every plan is supported by licensed providers and premium compounding pharmacies.
